



Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference

November 28, 2018

LEXINGTON, Mass., Nov. 28, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at Citi's 2018 Global Healthcare Conference on Wednesday, December 5, 2018 at the Lotte New York Palace Hotel in New York, NY.

About Aldeyra Therapeutics

Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

Corporate Contact:

David McMullin

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

dmcnullin@aldeyra.com

Investor Contact:

Chris Brinzey

Westwicke Partners

Tel: 339-970-2843

Chris.brinzey@westwicke.com

 View original content: <http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-participate-at-citis-2018-global-healthcare-conference-300756510.html>

SOURCE Aldeyra Therapeutics, Inc.